

## Amgen Inc. Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis

URL:	<a href="https://marketpublishers.com/r/AC6C8E87B63BEN.html">https://marketpublishers.com/r/AC6C8E87B63BEN.html</a>
Date:	October 15, 2018
Pages:	78
Price:	US\$ 499.00
ID:	AC6C8E87B63BEN

Amgen Inc. Due Diligence Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Amgen Inc. and its competitors. This provides our Clients with a clear understanding of Amgen Inc. position in the **Pharmaceuticals and Biotechnology Industry**.

- The report contains detailed information about Amgen Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Amgen Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.
- The Amgen Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.
- In the part that describes Amgen Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Amgen Inc. business.

### About Amgen Inc.

FY 2016 was a positive year for Amgen Inc.: its revenue increased by 6.14% to USD 22,991.0 billion compared to the previous year. Company's gross profit also grew from USD 17,487.0 million in 2015 to USD 18,829.0 million in 2016. Company's operating income rose by 13.94% to USD 9,832.0 million against FY 2015 as well as net income which rose up to USD 7,722.0 million.

Amgen, Inc., a biotechnology company, discovers, develops, manufactures, and markets human

therapeutics based on advances in cellular and molecular biology.

## Products

The company markets primarily recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. The company's principal products are: Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoietic-stimulating agents (ESAs) that stimulate the production of red blood cells; Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which selectively stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection), and Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body's response to inflammatory diseases.

The company's other marketed products include Sensipar/Mimpara (cinacalcet), a small molecule calcimimetic that lowers serum calcium levels; Vectibix (panitumumab), a fully human monoclonal antibody that binds specifically to the epidermal growth factor receptor (EGFr) and Nplate (romiplostim), a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production.

In addition to its marketed products, the company has products in mid-to-late stage development in various therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, and general medicine, which includes cardiology and neurology. Denosumab, its late-stage product candidate, is a fully human monoclonal antibody that specifically targets a ligand known as RANKL (that binds to a receptor known as RANK), an essential regulator of osteoclasts (the cells that break down bone) that is under regulatory review and is being studied across a range of conditions.

### Aranesp (darbepoetin alfa)

Aranesp is a protein that stimulates red blood cell production. Red blood cells transport oxygen to all cells of the body.

The company was granted an exclusive license by Kirin-Amgen, Inc. (KA), a joint venture between Kirin Holdings Company, Limited (Kirin) and Amgen, to manufacture and markets Aranesp in the United States, all European countries, Canada, Australia, New Zealand, Mexico, all Central and South American countries and certain countries in Central Asia, Africa, and the Middle East.

The company markets Aranesp primarily in the United States and Europe. Aranesp was launched in the United States and Europe for the treatment of anemia associated with CRF (both in patients on dialysis and patients not on dialysis) and is also indicated for the treatment of anemia due to concomitant chemotherapy in patients with non-myeloid malignancies.

### EPOGEN (Epoetin alfa)

EPOGEN is a protein that stimulates red blood cell production. A reduced red blood cell count can result in anemia.

The company was granted an exclusive license to manufacture and market EPOGEN in the United States under a licensing agreement with KA. The company has retained exclusive rights to market EPOGEN in the United States for dialysis patients. The company granted Ortho Pharmaceutical Corporation, a subsidiary of J&J (which has assigned its rights under the Product License Agreement to Centocor Ortho Biotech Products), a license to commercialize recombinant human erythropoietin as a human therapeutic in the United States in all markets other than dialysis.

The company launched EPOGEN in the United States for the treatment of anemia associated with CRF for patients who are on dialysis. The company markets EPOGEN in the United States for the treatment of

anemic adult and pediatric patients with CRF who are on dialysis.

Neulasta (pegfilgrastim)/NEUPOGEN (Filgrastim)

Neulasta is used for a pegylated protein, based on the Filgrastim molecule that selectively stimulates production of certain white blood cells known as neutrophils. Neutrophils defend against infection. NEUPOGEN is recombinant-methionyl human G-CSF, a protein that selectively stimulates production of neutrophils. Myelosuppressive chemothera

The above Company Fundamental Report is a half-ready report and contents are subject to change. It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

## Table of Content

### RESEARCH METHODOLOGY

### DISCLAIMER

## 1. AMGEN INC. COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

## 2. AMGEN INC. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

## 3. AMGEN INC. SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

## 4. AMGEN INC. FINANCIAL ANALYSIS

- 4.1. Financial Statements
  - 4.1.1. Income Statement
  - 4.1.2. Balance Sheet
  - 4.1.3. Cash Flow
- 4.2. Financial Ratios
  - 4.2.1. Profitability
  - 4.2.2. Margin Analysis

- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

## **5. AMGEN INC. COMPETITORS AND INDUSTRY ANALYSIS**

- 5.1. Amgen Inc. Direct Competitors
- 5.2. Comparison of Amgen Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of Amgen Inc. and Direct Competitors Stock Charts
- 5.4. Amgen Inc. Industry Analysis
  - 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  - 5.4.2. Amgen Inc. Industry Position Analysis

## **6. AMGEN INC. NEWS & EVENTS**

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

## **7. AMGEN INC. EXPERTS REVIEW<sup>1</sup>**

- 7.1. Experts Opinion
- 7.2. Experts Estimates

## **8. AMGEN INC. ENHANCED SWOT ANALYSIS<sup>2</sup>**

## **9. UNITED STATES PESTEL ANALYSIS<sup>2</sup>**

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors

## **10. AMGEN INC. IFE, EFE, IE MATRICES<sup>2</sup>**

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

## **11. AMGEN INC. PORTER FIVE FORCES ANALYSIS<sup>2</sup>**

## **12. AMGEN INC. VRIO ANALYSIS<sup>2</sup>**

## **APPENDIX: RATIO DEFINITIONS**

## **LIST OF TABLES**

Amgen Inc. Key Facts  
Profitability

Management Effectiveness  
Income Statement Key Figures  
Balance Sheet Key Figures  
Cash Flow Statement Key Figures  
Financial Performance Abbreviation Guide  
Amgen Inc. Key Executives  
Key Executives Biographies<sup>1</sup>  
Key Executives Compensations<sup>1</sup>  
Amgen Inc. Major Shareholders  
Amgen Inc. History  
Amgen Inc. Products  
Revenues by Segment  
Revenues by Region  
Amgen Inc. Offices and Representations  
Amgen Inc. SWOT Analysis  
Yearly Income Statement Including Trends  
Income Statement Latest 4 Quarters Including Trends  
Yearly Balance Sheet Including Trends  
Balance Sheet Latest 4 Quarters Including Trends  
Yearly Cash Flow Including Trends  
Cash Flow Latest 4 Quarters Including Trends  
Amgen Inc. Profitability Ratios  
Margin Analysis Ratios  
Asset Turnover Ratios  
Credit Ratios  
Long-Term Solvency Ratios  
Financial Ratios Growth Over Prior Year  
Amgen Inc. Capital Market Snapshot  
Amgen Inc. Direct Competitors Key Facts  
Direct Competitors Profitability Ratios  
Direct Competitors Margin Analysis Ratios  
Direct Competitors Asset Turnover Ratios  
Direct Competitors Credit Ratios  
Direct Competitors Long-Term Solvency Ratios  
Pharmaceuticals and Biotechnology Industry Statistics  
Amgen Inc. Industry Position  
Company vs. Industry Income Statement Analysis  
Company vs. Industry Balance Sheet Analysis  
Company vs. Industry Cash Flow Analysis  
Company vs. Industry Ratios Comparison  
Amgen Inc. Consensus Recommendations<sup>1</sup>  
Analyst Recommendation Summary<sup>1</sup>  
Price Target Summary<sup>1</sup>  
Experts Recommendation Trends<sup>1</sup>  
Revenue Estimates Analysis<sup>1</sup>  
Earnings Estimates Analysis<sup>1</sup>  
Historical Surprises<sup>1</sup>  
Revenue Estimates Trend<sup>1</sup>  
Earnings Estimates Trend<sup>1</sup>  
Revenue Revisions<sup>1</sup>

## LIST OF FIGURES

Amgen Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit

Profit Margin Chart  
Operating Margin Chart  
Return on Equity (ROE) Chart  
Return on Assets (ROA) Chart  
Debt to Equity Chart  
Current Ratio Chart  
Amgen Inc. 1-year Stock Charts  
Amgen Inc. 5-year Stock Charts  
Amgen Inc. vs. Main Indexes 1-year Stock Chart  
Amgen Inc. vs. Direct Competitors 1-year Stock Charts  
Amgen Inc. Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses.

The complete financial data is available for publicly traded companies.

### I would like to order:

**Product name:** Amgen Inc. Due Diligence Report Including Financial, SWOT, Competitors and Industry Analysis  
**Product link:** <https://marketpublishers.com/r/AC6C8E87B63BEN.html>  
**Product ID:** AC6C8E87B63BEN  
**Price:** US\$ 499.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/AC6C8E87B63BEN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**